Eli Lilly and Company (LLY)vsNeurocrine Biosciences Inc (NBIX)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
NBIX
Neurocrine Biosciences Inc
$156.22
-0.22%
HEALTHCARE · Cap: $15.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2261% more annual revenue ($79.67B vs $3.37B). LLY leads profitability with a 33.5% profit margin vs 20.9%. NBIX appears more attractively valued with a PEG of 0.31. NBIX earns a higher WallStSmart Score of 81/100 (A-).
LLY
Strong Buy76
out of 100
Grade: B+
NBIX
Exceptional Buy81
out of 100
Grade: A-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Growing faster than its price suggests
Revenue surging 39.5% year-over-year
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.2%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, Altman Z-Score. Profitability is solid with margins at 20.9% and operating margin at 22.2%. Revenue growth of 39.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NBIX scores higher overall (81/100 vs 76/100), backed by strong 20.9% margins and 39.5% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?